Previous studies suggested that AMPK activators, including metformin, can improve insulin resistance, liver steatosis, and dyslipidemia through the inactivation of sterol regulatory element-binding protein (SREBP) [37], hepatic stellate cell activation [38,39], and the TGF-β1/Smad3 pathway [40]. This evidence concerns the gene TGFB1 and fatty liver disease.